Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitors in Calcific Aortic Valve Stenosis
NCT04968509Phase 3Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of evolocumab, alirocumab and tafolecimab in calcific aortic stenosis (AS) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Average annual change in peak aortic jet velocity at 24 months. Started Mar 2024; status: recruiting.
02
Drugs
evolocumabalirocumabtafolecimab
03
Conditions
calcific aortic stenosis (AS)
Beyond the preview
Go deeper on NCT04968509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968509.